Aileron Therapeutics (NASDAQ:ALRN) PT Raised to $19.00 at LADENBURG THALM/SH SH

Aileron Therapeutics (NASDAQ:ALRN) had its price objective lifted by analysts at LADENBURG THALM/SH SH from $9.00 to $19.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s price target suggests a potential upside of 300.84% from the stock’s current price.

Aileron Therapeutics Stock Down 5.2 %

Aileron Therapeutics stock opened at $4.74 on Thursday. The company’s 50-day moving average price is $5.39 and its 200-day moving average price is $3.62. The company has a market cap of $23.18 million, a PE ratio of -1.40 and a beta of 2.22. Aileron Therapeutics has a twelve month low of $1.01 and a twelve month high of $7.42.

Institutional Investors Weigh In On Aileron Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC lifted its stake in shares of Aileron Therapeutics by 65.5% in the 3rd quarter. Renaissance Technologies LLC now owns 190,691 shares of the company’s stock valued at $39,000 after purchasing an additional 75,500 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Aileron Therapeutics by 52.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock valued at $38,000 after buying an additional 63,651 shares during the period. Geode Capital Management LLC lifted its position in Aileron Therapeutics by 23.2% in the first quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock worth $68,000 after buying an additional 10,311 shares during the last quarter. Sigma Planning Corp purchased a new position in Aileron Therapeutics during the fourth quarter worth $51,000. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in Aileron Therapeutics during the fourth quarter valued at $48,000. 90.89% of the stock is owned by institutional investors.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.